Tanespimycin

URI: https://gptkb.org/entity/Tanespimycin

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:chemical_compound antineoplastic agent
gptkbp:alternativeName	gptkb:17-allylamino-17-demethoxygeldanamycin gptkb:17-AAG
gptkbp:ATCCode	none
gptkbp:CASNumber	75747-14-7
gptkbp:clinicalTrialPhase	Phase II
gptkbp:derivedFrom	gptkb:geldanamycin
gptkbp:developedBy	antineoplastic agent
gptkbp:has_clinical_use	investigational cancer therapy
gptkbp:has_KEGG_Drug_ID	D08913
gptkbp:hasMolecularFormula	C31H43N3O8
gptkbp:hasSMILES	CN(C)C1C(C(C(O1)NC(=O)C=CSC2=CC=CC=C2)O)O
gptkbp:hasUNII	6J8T4C8A7I
https://www.w3.org/2000/01/rdf-schema#label	Tanespimycin
gptkbp:IUPACName	(2E)-N-[(2R,3S,4R,5R)-5-(dimethylamino)-3,4-dihydroxy-2-methyloxan-2-yl]-3-(phenylmethylsulfanyl)prop-2-enamide
gptkbp:mechanismOfAction	Hsp90 inhibitor
gptkbp:meltingPoint	~180°C
gptkbp:molecularWeight	585.69 g/mol
gptkbp:PubChem_CID	2340961 3081377 CHEMBL25444
gptkbp:routeOfAdministration	intravenous
gptkbp:synonym	KOS-953 NSC 330507
gptkbp:target	Hsp90 protein
gptkbp:bfsParent	gptkb:17-AAG
gptkbp:bfsLayer	8